Saturday - June 13, 2026
Boehringer Ingelheim's Oncology Portfolio Shows Strong Promise Across Multiple Cancers at ASCO 2026
May 21, 2026
INGELHEIM AM RHEIN, Germany, May 21 (TNSrep) -- Boehringer Ingelheim, a pharmaceutical company, issued the following news release:

* * *

Boehringer Ingelheim's oncology portfolio shows strong promise across multiple cancers at ASCO 2026

* New patient-reported outcomes data shows improved function and reduced symptom burden with HERNEXEOS(R) (zongertinib tablets) as an initial treatment option in HER2 (ERBB2)-mutant advanced non-small cell lung cancer . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products